Advicenne S.A. (ALDVI.PA)
EUR 1.67
(0.12%)
EUR 1.67
(0.12%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -6.24 Million EUR | 35.81% |
| 2022 | -9.87 Million EUR | 19.06% |
| 2021 | -12.03 Million EUR | 14.01% |
| 2020 | -13.97 Million EUR | 0.24% |
| 2019 | -14 Million EUR | -184.28% |
| 2018 | -4.96 Million EUR | 2.41% |
| 2017 | -5.04 Million EUR | -64.63% |
| 2016 | -3.54 Million EUR | 8.31% |
| 2015 | -3.79 Million EUR | -89.19% |
| 2014 | -1.76 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.59 Million EUR | 0.0% |
| 2024 Q1 | -1.59 Million EUR | 12.8% |
| 2023 Q1 | -1.45 Million EUR | 75.09% |
| 2023 Q2 | -2.97 Million EUR | -105.24% |
| 2023 Q3 | -1.83 Million EUR | 38.46% |
| 2023 FY | - EUR | 35.81% |
| 2023 Q4 | -1.83 Million EUR | 0.0% |
| 2022 Q3 | -2.81 Million EUR | 37.17% |
| 2022 Q1 | -2.06 Million EUR | 61.76% |
| 2022 FY | - EUR | 19.06% |
| 2022 Q4 | -5.82 Million EUR | -106.56% |
| 2022 Q2 | -4.48 Million EUR | -116.98% |
| 2021 FY | - EUR | 14.01% |
| 2021 Q4 | -5.4 Million EUR | -128.44% |
| 2021 Q3 | -2.36 Million EUR | 69.26% |
| 2021 Q2 | -7.69 Million EUR | -110.15% |
| 2021 Q1 | -3.66 Million EUR | 41.25% |
| 2020 Q4 | -6.23 Million EUR | -97.22% |
| 2020 Q1 | -3.81 Million EUR | 48.34% |
| 2020 Q3 | -3.16 Million EUR | 58.11% |
| 2020 Q2 | -7.54 Million EUR | -97.75% |
| 2020 FY | - EUR | 0.24% |
| 2019 Q3 | -3.66 Million EUR | 45.17% |
| 2019 Q1 | -3.23 Million EUR | -290.78% |
| 2019 FY | - EUR | -184.28% |
| 2019 Q4 | -7.38 Million EUR | -101.39% |
| 2019 Q2 | -6.69 Million EUR | -107.09% |
| 2018 Q4 | -826.93 Thousand EUR | 0.0% |
| 2018 Q3 | -826.93 Thousand EUR | 57.8% |
| 2018 Q1 | -1.95 Million EUR | -7.22% |
| 2018 Q2 | -1.95 Million EUR | 0.0% |
| 2018 FY | - EUR | 2.41% |
| 2017 Q4 | -1.82 Million EUR | 0.0% |
| 2017 Q2 | -1.11 Million EUR | 0.0% |
| 2017 Q1 | -1.11 Million EUR | -43.21% |
| 2017 FY | - EUR | -64.63% |
| 2017 Q3 | -1.82 Million EUR | -64.34% |
| 2016 FY | - EUR | 8.31% |
| 2016 Q1 | -759.5 Thousand EUR | 0.0% |
| 2016 Q2 | -759.5 Thousand EUR | 0.0% |
| 2016 Q3 | -776.5 Thousand EUR | -2.24% |
| 2016 Q4 | -776.5 Thousand EUR | 0.0% |
| 2015 FY | - EUR | -89.19% |
| 2014 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -89.787% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 95.313% |
| Adocia SA | -22.73 Million EUR | 72.532% |
| Aelis Farma SA | -6.34 Million EUR | 1.623% |
| Biophytis S.A. | -13.8 Million EUR | 54.767% |
| genOway Société anonyme | 6.35 Million EUR | 198.319% |
| IntegraGen SA | -52.5 Thousand EUR | -11792.654% |
| Medesis Pharma S.A. | -3.84 Million EUR | -62.398% |
| Neovacs S.A. | -8.44 Million EUR | 26.103% |
| NFL Biosciences SA | -4.04 Million EUR | -54.199% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 8708.852% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -117.297% |
| Sensorion SA | -22.31 Million EUR | 72.017% |
| Theranexus Société Anonyme | -7.38 Million EUR | 15.476% |
| TME Pharma N.V. | -5.07 Million EUR | -23.107% |
| Valbiotis SA | -6.95 Million EUR | 10.223% |
| TheraVet SA | -517.33 Thousand EUR | -1106.953% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 66.991% |
| argenx SE | -199.5 Million EUR | 96.87% |
| BioSenic S.A. | -6.79 Million EUR | 8.122% |
| Celyad Oncology SA | -7.76 Million EUR | 19.567% |
| DBV Technologies S.A. | -79.53 Million EUR | 92.149% |
| Galapagos NV | 51.03 Million EUR | 112.234% |
| Genfit S.A. | -28.05 Million EUR | 77.741% |
| GeNeuro SA | -14.31 Million EUR | 56.39% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 58.318% |
| Innate Pharma S.A. | -7.57 Million EUR | 17.604% |
| Inventiva S.A. | -101.84 Million EUR | 93.869% |
| MaaT Pharma SA | -19.74 Million EUR | 68.369% |
| MedinCell S.A. | -20.04 Million EUR | 68.852% |
| Nanobiotix S.A. | -34.01 Million EUR | 81.646% |
| Onward Medical N.V. | -35.23 Million EUR | 82.278% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -40.841% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 73.163% |
| Oxurion NV | -16.72 Million EUR | 62.676% |
| Pharming Group N.V. | 4.98 Million EUR | 225.357% |
| Poxel S.A. | -12.17 Million EUR | 48.731% |
| GenSight Biologics S.A. | -21.73 Million EUR | 71.266% |
| Transgene SA | -27.02 Million EUR | 76.895% |
| Financière de Tubize SA | 184.57 Thousand EUR | 3482.98% |
| UCB SA | 1.26 Billion EUR | 100.492% |
| Valneva SE | -64.51 Million EUR | 90.322% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 77.978% |